Short Hospital Stays Don't Impair STEMI Outcomes in Seniors

Share this content:
Short Hospital Stays Don't Impair STEMI Outcomes in Seniors
Short Hospital Stays Don't Impair STEMI Outcomes in Seniors

WEDNESDAY, March 25, 2015 (HealthDay News) -- For older patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), outcomes are similar for discharge after 48 hours versus four to five days, according to a study published in the March 31 issue of the Journal of the American College of Cardiology.

Rajesh V. Swaminathan, M.D., from Weill Cornell Medical College in New York City, and colleagues examined whether shorter length of stay (LOS) is safe for older patients undergoing PCI for STEMI. Data were collected for 33,920 patients with STEM who were ≥65 years of age and treated with primary PCI from 2004 to 2009. Overall, 26.9, 46.3, and 26.8 percent of patients had short (no more than three days), medium (four to five days), and long (more than five days) LOS, respectively.

The researchers found that for medium versus short LOS there were no significant differences in 30-day all-cause mortality (hazard ratio [HR], 1.00; 95 percent confidence interval [CI], 0.74 to 1.34) or in major adverse cardiac events (MACE [death, readmission for myocardial infarction, unplanned revascularization]) (HR, 1.03; 95 percent CI, 0.86 to 1.25). For long versus short LOS there were significant increases in adjusted mortality (HR, 2.30; 95 percent CI, 1.72 to 3.07) and MACE (HR, 1.75; 95 percent CI, 1.44 to 2.12). Significantly increased 30-day mortality and MACE were seen for patients with a very short LOS (one to two days) versus three- to four-day LOS.

"Early, but not very early (<48 hours), discharge may be safe among selected older patients with STEMI," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »